Sanofi SA (MEX:SNY)
MXN 852 -22 (-2.52%) Market Cap: 2.13 Til Enterprise Value: 2.32 Til PE Ratio: 20.38 PB Ratio: 1.48 GF Score: 75/100

Sanofi SA at Leerink Partners Global Biopharma Conference Transcript

Mar 12, 2024 / 02:40PM GMT
Release Date Price: MXN807.56
David Reed Risinger
Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst

All right. Good morning, everyone. So my name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners, and it's very much my pleasure to welcome you to this session with Sanofi. And I am pleased that we're able to be joined by the 2 key leaders of the Immunology franchise at the company. So Shaju Backer to my immediate left, is the Global Head of the Immunology franchise; Naimish Patel is the Global Head of Development for Immunology and Inflammation. And so thank you both for being with us today.

Questions & Answers

David Reed Risinger
Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst

And it's actually great timing on the heels of AAD. And so I thought maybe you could start with just some comments on the momentum for the company and quick takeaways from AAD.

Shaju Backer
Sanofi - Global Head of Immunology Franchise

Sure. So Naimish, I might talk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot